Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis.
about
Personalized medicine in gastric cancer: Where are we and where are we going?Advanced gastric cancer: What we know and what we still have to learnHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsHER2 expression in gastric and oesophageal cancer: a meta-analytic reviewS-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 TrialAssociation of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients.Targeted therapy in gastric cancer.Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.Association of HER2 codon 655 polymorphism with ovarian cancer.Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2-Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis.Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma.Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.TFF3 and HER2 expression and their correlation with survival in gastric cancer.Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.Optimal management of resected gastric cancer.
P2860
Q26774521-BBC06934-73CA-459D-AE4A-B9A9BD6EE4EAQ26774528-B376E390-66B4-4D54-9275-BDF0D07B0195Q28078111-F0D38BE6-0C1A-44EF-B9B5-D2B3EF7974A6Q35029025-E697CC95-8F18-471F-9589-D92E8D6989B5Q36194219-945D2A80-25C4-4A8C-A8BC-F916EDD5EB4CQ37012387-DC5C00B8-BE6A-4525-9061-1C6EBC7C835CQ37392861-FC78FC4F-9381-41AC-8100-5ABBBD07D9E8Q37523508-6A87D22D-7424-410B-81FE-1ACD7FE9BD38Q38364292-B4FC1A09-BFCC-4E8C-889D-1E8B6A7D2038Q39453559-04A3360B-D4DB-4389-B5C9-5A946B9B6904Q40212670-B5513078-76E4-4E7B-A79D-EA3D9A309B4DQ47190729-BACE5D5F-E904-4931-99BD-3551A2B394B6Q51180085-C9513253-722F-465B-BABD-C8D9CEC806CAQ52880999-0B2BE1D8-6E0E-4042-A53D-4633F8C6D152Q53667030-D5B6A14B-DA41-4857-8C3E-CA8350972D92Q54316753-05FCE3D4-A065-4DA9-9E5D-6A70E4371F26Q55359616-35B6A238-D545-475A-9D45-159FC8ADFB84
P2860
Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Prognostic significance of HER ...... cer: an updated meta-analysis.
@en
Prognostic significance of HER2 expression based on trastuzumab for gastric cancer
@nl
type
label
Prognostic significance of HER ...... cer: an updated meta-analysis.
@en
Prognostic significance of HER2 expression based on trastuzumab for gastric cancer
@nl
prefLabel
Prognostic significance of HER ...... cer: an updated meta-analysis.
@en
Prognostic significance of HER2 expression based on trastuzumab for gastric cancer
@nl
P2093
P2860
P1433
P1476
Prognostic significance of HER ...... cer: an updated meta-analysis.
@en
P2093
Jianchun Gu
Leizhen Zheng
Meiling Zhu
Xiaoping Li
Yajie Wang
P2860
P2888
P304
P356
10.1007/S13277-014-1693-7
P577
2014-02-21T00:00:00Z
P6179
1022451369